Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12273-12290

  Hung, Tsai Hsien ^a   Hsu, Sheng Chi ^b   Cheng, Ching Yi ^c   Choo, Kong Bung ^d   Tseng, Ching Ping ^a   Chen, Tse Ching ^b   Lan, Ying Wei ^a   Huang, Tsung Teng ^a   Lai, Hsin Chih ^a   Chen, Chuan Mu ^e   Chong, Kowit Yu ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cell cycle; Multiple drug resistance; shRNA; Wnt5A

Indexed keywords

BETA CATENIN; CRE RECOMBINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; DOXORUBICIN; LEF PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; SHORT HAIRPIN RNA; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT5A PROTEIN; ANTINEOPLASTIC AGENT; NEUTRALIZING ANTIBODY; WNT5A PROTEIN ANTIBODY; ABCB1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; ONCOPROTEIN; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG RESISTANCE; ENZYME ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MULTIDRUG RESISTANCE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; TUMOR VOLUME; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL LINE; CANCER INHIBITION; CLINICAL ARTICLE; CYCLIC AMP RESPONSIVE ELEMENT; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE EXPRESSION; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UTERUS SARCOMA; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; METABOLISM; NUDE MOUSE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; P-GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919964490     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2631     Document Type: Article

References (73)

1. Binkhathlan Z and Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013; 13: 326-346.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-234.
3. Thomas H and Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003; 10: 159-165.
4. Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW and Murph MM. Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010; 9: 289.
5. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y and Takahashi N. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012; 18: 405-412.
6. Nusse R. Wnt signaling and stem cell control. Cell Res. 2008; 18: 523-527.
7. Anitha P, Priyadarsini RV, Kavitha K, Thiyagarajan P and Nagini S. Ellagic acid coordinately attenuates Wnt/beta-catenin and NF-kappaB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis. Eur J Nutr. 2013; 52: 75-84.
8. Paul I, Bhattacharya S, Chatterjee A, Ghosh MK. Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk. Genes Cancer.2013; 4: 427-446.
9. Jiang J, Griffin JD. Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner. Genes Cancer. 2010; 1: 164-176.
10. Kaur N, Chettiar S, Rathod S, Rath P, Muzumdar D, Shaikh ML and Shiras A. Wnt3a mediated activation of Wnt/beta-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci. 2013; 54: 44-57.
11. Fanto M and McNeill H. Planar polarity from flies to vertebrates. J Cell Sci. 2004; 117: 527-533.
12. Kohn AD and Moon RT. Wnt and calcium signaling: betacatenin-independent pathways. Cell Calcium. 2005; 38: 439-446.
13. Keeble TR, Halford MM, Seaman C, Kee N, Macheda M, Anderson RB, Stacker SA and Cooper HM. The Wnt receptor Ryk is required for Wnt5a-mediated axon guidance on the contralateral side of the corpus callosum. J Neurosci. 2006; 26: 5840-5848.
14. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, 3rd and Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003; 423: 448-452.
15. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL and Moon RT. Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol. 1996; 133: 1123-1137.
16. Menck K, Klemm F, Gross JC, Pukrop T, Wenzel D, Binder C. Induction and transport of Wnt 5a during macrophageinduced malignant invasion is mediated by two types of extracellular vesicles. Oncotarget. 2013; 4: 2057-2066.
17. McDonald SL and Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer. 2009; 101: 209-214.
18. Correa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L and Abdelhay E. Wnt/beta-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 2012; 12: 303.
19. Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, Xiang L, Gao P and Zhou G. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett. 2012; 323: 106-113.
20. Chong KY, Hsu CJ, Hung TH, Hu HS, Wang TH, Wang CH, Chen CM, Choo KB, Lai HC and Tseng CP. Wnt pathway activation and ABCB1 expression account for attenuation of proteasome Inhibitor-mediated apoptosis in multidrug-resistant cancer cells. Cancer Biol Ther (in press, doi: 10.4161/15384047.2014.987093)
21. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC and Plass C. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004; 64: 2424-2433.
22. Torii K, Nishizawa K, Kawasaki A, Yamashita Y, Katada M, Ito M, Nishimoto I, Terashita K, Aiso S and Matsuoka M. Anti-apoptotic action of Wnt5a in dermal fibroblasts is mediated by the PKA signaling pathways. Cell Signal. 2008; 20: 1256-1266.
23. Wu KJ, Mattioli M, Morse HC, 3rd and Dalla-Favera R. c-MYC activates protein kinase A (PKA) by direct transcriptional activation of the PKA catalytic subunit beta (PKA-C beta) gene. Oncogene. 2002; 21: 7872-7882.
24. Zhu Y, Yao J, Meng Y, Kasai A, Hiramatsu N, Hayakawa K, Miida T, Takeda M, Okada M and Kitamura M. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system. Br J Pharmacol. 2006; 148: 833-844.
25. Angelini A, Di Febbo C, Ciofani G, Di Nisio M, Baccante G, Di Ilio C, Cuccurullo F and Porreca E. Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. Cancer Biol Ther. 2005; 4: 313-317.
26. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, Romero IA, Couraud PO, Weksler BB, Hladky SB and Barrand MA. Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008; 106: 1855-1865.
27. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph JM, Muhlethaler-Mottet A and Gross N. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene. 2009; 28: 2245-2256.
28. Hung TH, Chen CM, Tseng CP, Shen CJ, Wang HL, Choo KB, Chong KY. FZD1 activates protein kinase C deltamediated drug-resistance in multidrug-resistant MES-SA/ Dx5 cancer cells. Int J Biochem Cell Biol. 2014; 53: 55-65.
29. Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, Hite KM, Schlag PM, Shoemaker RH and Walther W. Impact of mutant beta-catenin on ABCB1 expression and therapy response in colon cancer cells. Br J Cancer. 2012; 106: 1395-1405.
30. Labialle S, Gayet L, Marthinet E, Rigal D and Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol. 2002; 64: 943-948.
31. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H and Katano M. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 2010; 30: 2041-2048.
32. Shen DY, Zhang W, Zeng X and Liu CQ. Inhibition of Wnt/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci. 2013; 104: 1303-1308.
33. Lee WK, Chakraborty PK and Thevenod F. Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1. Int J Cancer. 2013; 133: 556-567.
34. Huang GL, Luo Q, Rui G, Zhang W, Zhang QY, Chen QX and Shen DY. Oncogenic activity of retinoic acid receptor gamma is exhibited through activation of the Akt/NF-kappaB and Wnt/beta-catenin pathways in cholangiocarcinoma. Mol Cell Biol. 2013; 33: 3416-3425.
35. Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L and Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep. 2005; 14: 925-932.
36. Peng C, Zhang X, Yu H, Wu D and Zheng J. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer. 2011; 21: 280-288.
37. Bordonaro M, Tewari S, Cicco CE, Atamna W and Lazarova DL. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One. 2011; 6: e27308.
38. Griesmann H, Ripka S, Pralle M, Ellenrieder V, Baumgart S, Buchholz M, Pilarsky C, Aust D, Gress TM and Michl P. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia. 2013; 15: 11-22.
39. Cvijic ME and Chin KV. Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants. Cell Growth Differ. 1997; 8: 1243-1247.
40. Nesterova MV, Johnson NR, Stewart T, Abrams S and Cho-Chung YS. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy. Clin Cancer Res. 2005; 11: 5950-5955.
41. Cvijic ME, Yang WL and Chin KV. Cisplatin resistance in cyclic AMP-dependent protein kinase mutants. Pharmacol Ther. 1998; 78: 115-128.
42. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, Neefjes J and Michalides R. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J. 2007; 26: 3534-3544.
43. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC, Landberg G and Michalides R. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat. 2011; 125: 1-12.
44. Gu L, Lau SK, Loera S, Somlo G and Kane SE. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin Cancer Res. 2009; 15: 7196-7206.
45. Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG and de Vere White RW. Dual blockade of PKA and NF-kappaB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011; 2: 224-238.
46. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L and Ciardiello F. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer. 2012; 106: 1648-1659.
47. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramirez T, Vela T, Candelaria M, Camargo MF, Robles E, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006; 1: e98.
48. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP and Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper-and hypomethylated targets. Mol Cancer Ther. 2007; 6: 1089-1098.
49. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X and Nelson WG. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther. 2004; 3: 540-548.
50. Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA and Brown KD. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis. 2008; 29: 510-518.
51. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV and Pogribny IP. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett. 2006; 231: 87-93.
52. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS and Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006; 108: 3881-3889.
53. Munoz M, Henderson M, Haber M and Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007; 59: 752-757.
54. Ludwig JA, Szakacs G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN and Gottesman MM. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 2006; 66: 4808-4815.
55. Matono H, Tamiya S, Yokoyama R, Saito T, Iwamoto Y, Tsuneyoshi M and Oda Y. Abnormalities of the Wnt/betacatenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between beta-catenin widespread nuclear expression and VEGF overexpression. Histopathology. 2011; 59: 368-375.
56. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H and Ueno M. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol. 2005; 23: 8765-8773.
57. Syed Khaja AS, Helczynski L, Edsjo A, Ehrnstrom R, Lindgren A, Ulmert D, Andersson T and Bjartell A. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One. 2011; 6: e26539.
58. Cao B, Jia J, Ma L, Di L, Song G, Yuan Y, Ma B, Zhu Y, Yu J, Wang X, Zhou X, Lyerly HK and Ren J. Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. Clin Transl Oncol. 2012; 14: 575-585.
59. Li L, Jiang AC, Dong P, Wang H, Xu W and Xu C. MDR1/ P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol. 2009; 16: 1421-1428.
60. Harker WG and Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985; 45: 4091-4096.
61. Ke W, Yu P, Wang J, Wang R, Guo C, Zhou L, Li C, Li K. MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research. Med Oncol. 2011; 28: S135-141.
62. Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV and Hsu SC. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol. 2013; 85: 325-334.
63. Levatić J, Ćurak J, Kralj M, Šmuc T, Osmak M and Supek F. Accurate models for P-gp drug recognition induced from a cancer cell line cytotoxicity screen. J Med Chem. 2013; 56: 5691-5708.
64. Fan CW, Chan CC, Chao CC, Fan HA, Sheu DL and Chan EC. Expression patterns of cell cycle and apoptosis-related genes in a multidrug-resistant human colon carcinoma cell line. Scand J Gastroenterol. 2004; 39: 464-469.
65. Chong KY, Lai CC, Su CY. Inducible and constitutive HSP70s confer synergistic resistance against metabolic challenges. Biochem Biophys Res Commun. 2013; 430: 774-779.
66. Huang CL, Cheng JC, Kitajima K, Nakano T, Yeh CF, Chong KY, Tseng CP. Disabled-2 is required for mesoderm differentiation of murine embryonic stem cells. J Cell Physiol. 2010; 225: 92-105.
67. Cailotto F, Sebillaud S, Netter P, Jouzeau JY and Bianchi A. The inorganic pyrophosphate transporter ANK preserves the differentiated phenotype of articular chondrocyte. J Biol Chem. 2010; 285: 10572-10582.
68. Shen CJ, Cheng WT, Wu SC, Chen HL, Tsai TC, Yang SH and Chen CM. Differential differences in methylation status of putative imprinted genes among cloned swine genomes. PLoS One. 2012; 7: e32812.
69. Xiong Z and Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997; 25: 2532-2534.
70. Huang TT, Chong KY, Ojcius DM, Wu YH, Ko YF, Wu CY, Martel J, Lu CC, Lai HC, Young JD. Hirsutella sinensis mycelium suppresses interleukin-1β and interleukin-18 secretion by inhibiting both canonical and non-canonical inflammasomes. Sci Rep. 2013; 3: 1374.
71. Kum WW, Lo BC, Yu HB and Finlay BB. Protective role of Akt2 in Salmonella enterica serovar typhimurium-induced gastroenterocolitis. Infect Immun. 2011; 79: 2554-2566.
72. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R. Semiquantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol. 2012; 25: 869-876.
73. Arias-Pulido H, Chaher N, Gong Y, Qualls C, Vargas J, Royce M. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer. BMC Cancer. 2012; 12: 298.